HAEMOCELL LIMITED

06063361
Active United Kingdom

Manufacture of medical and dental instruments and supplies

0 employees website.com
Manufacture of medical and dental instruments and supplies
H

HAEMOCELL LIMITED

06063361

Manufacture of medical and dental instruments and supplies

Founded 24 Jan 2007 Active United Kingdom 0 employees website.com
Manufacture of medical and dental instruments and supplies

Previous Company Names

COBRA MEDICAL LIMITED 19 May 2008 — 5 Jun 2008
HAEMOCELL LIMITED 24 Jan 2007 — 19 May 2008
Accounts Submitted 25 Sept 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 10 Jun 2026 Next due 7 Feb 2027 7 months remaining
Net assets £383K £9K 2024 year on year
Total assets £388K £9K 2024 year on year
Total Liabilities £5K £18K 2024 year on year
Charges 2
1 outstanding 1 satisfied

Contact & Details

Contact

Full company profile for HAEMOCELL LIMITED (06063361), an active company based in United Kingdom. Incorporated 24 Jan 2007. Manufacture of medical and dental instruments and supplies. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type audit-exemption-subsidiary
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Balance Sheet & P&L (2013–2024)

Cash in Bank

N/A

Decreased by £31.00k (-100%)

Net Assets

£383.00k

Increased by £9.00k (+2%)

Total Liabilities

£5.00k

Decreased by £18.00k (-78%)

Turnover

£11.00k

Increased by £6.00k (+120%)

Employees

N/A

Debt Ratio

1%

Decreased by 5 (-83%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (1)

Surgical Innovations Plc
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active
Active
Notified 6 Apr 2016
Nature of Control
  • Ownership Of Shares 75 To 100 Percent

Group Structure

Group Structure

HAEMOCELL LIMITED Current Company

Charges

Charges

1 outstanding 1 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
10 Jun 2026Confirmation StatementConfirmation statement made on 24 Jan 2026 with no updates
31 May 2026OfficersAppointment of David John Marsh as director
31 May 2026OfficersAppointment of David John Marsh as director
10 Oct 2025OfficersAppointment of Mr Brent Raymond Greetham as director on 29 Sept 2025
6 Oct 2025OfficersTermination of Keyvan Mehdi Djamarani as director on 29 Sept 2025
10 Jun 2026 Confirmation Statement

Confirmation statement made on 24 Jan 2026 with no updates

31 May 2026 Officers

Appointment of David John Marsh as director

31 May 2026 Officers

Appointment of David John Marsh as director

10 Oct 2025 Officers

Appointment of Mr Brent Raymond Greetham as director on 29 Sept 2025

6 Oct 2025 Officers

Termination of Keyvan Mehdi Djamarani as director on 29 Sept 2025

Recent Activity

Latest Activity

Confirmation statement made on 24 Jan 2026 with no updates

1 weeks ago on 10 Jun 2026

Appointment of David John Marsh as director

2 weeks ago on 31 May 2026

Appointment of David John Marsh as director

2 weeks ago on 31 May 2026

Appointment of Mr Brent Raymond Greetham as director on 29 Sept 2025

8 months ago on 10 Oct 2025

Termination of Keyvan Mehdi Djamarani as director on 29 Sept 2025

8 months ago on 6 Oct 2025